Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
29 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
150.8 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CABINET DU DR NOUREDDINE MESSAFEUR
15 RUE DU MARECHAL FOCH, 14100 LISIEUX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Health science reports · 2025
ABSTRACTIntroductionSince the advent of highly active antiretroviral therapy (HAART), morbidity and mortality rates associated with human immunodeficiency virus (HIV) have significantly decreased leading to prolonged life span of Individuals living with HIV due to the effectiveness of antiretroviral therapy. However, this prolonged lifespan alone does not fully account for the increased incidence of cardiometabolic complications. These complications result from a complex interplay of factors such as chronic inflammation, immune activation, ART‐related metabolic effects, and lifestyle changes. which contribute to elevated morbidity and mortality rates, therefore requiring a deeper understanding and setting effective management strategies. This review aims at providing insights and a nuanced understanding of the relationship between HIV and cardiometabolic disorders, explore their clinical implications and adapt optimal management strategies to address the multifaceted challenges at the intersection of HIV and cardiometabolic health, ultimately enhancing patient outcomes and quality of life.MethodsData retrieval was conducted using a predetermined search strategy from medical journals that were published in bibliographical databases like PubMed, Science Direct and Embase. This review systematically considered and synthesized current literature on the association between cardiometabolic challenges and HIV.ResultsThis review provides a detailed exploration of the interrelationship between HIV and cardiometabolic challenges, with an emphasis on insights, impact, and best practices for optimal management. It underscores the high risk of cardiovascular disease, insulin resistance, dyslipidemia, and lipodystrophy in people living with HIV. Recommendations include evidence‐based approaches such as routine cardiometabolic risk. Prevention, screening, management, lifestyle interventions (diet and exercise), and optimizing ART regimens to reduce the negative health outcomes experienced by people living with HIV and to direct clinical practice. To reduce health issues, enhance clinical results, and improve the long‐term quality of life for people living with HIV, it is important to early identify cardiovascular risk factors and to follow customized prevention and management methods.ConclusionThis review shows that early detection through regular screening is pivotal through collaboration between healthcare providers, researchers, and policymakers which will allow for timely interventions and drive innovation and address evolving challenges to enhancing the quality of life for individuals living with HIV. Continuing to do research and advocacy efforts, will not only advance knowledge but also optimize the long‐term health outcomes for people living with HIV.
Kidney360 · 2025
Key Points Twenty-seven percent of patients with autosomal dominant polycystic kidney disease discontinued tolvaptan in a real-world cohort in the midwestern United States.Most patients maintained tolvaptan on lower doses than trials, and a minority tolerated above the 45 mg (am)/15 mg (pm) starting dosage.Adverse effects, specifically aquaretic side effects, strongly influenced tolvaptan tolerability, dosage titration, and discontinuation. Background Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disease leading to kidney failure. Tolvaptan, a vasopressin V2 receptor antagonist, is the only medication approved by the US Food and Drug Administration for slowing kidney growth in individuals with rapidly progressive ADPKD, but its long-term tolerability and effective implementation has yet to be studied, particularly in real-world clinical settings within the United States. Methods This retrospective cohort study examined adults with ADPKD treated with tolvaptan at the University of Kansas Medical Center and the University of Iowa Hospitals & Clinics from May 2018 to April 2023. Data on demographics, clinical characteristics, tolvaptan dosage, and treatment duration were collected from electronic health records for an average follow-up duration of 28.2 months (interquartile range: 8.5–47.1 months). The study focused on examining tolvaptan dosage trends, treatment discontinuation reasons, and the impact of aquaretic side effects on dosage and adherence. Results Of 134 patients, 27% stopped tolvaptan during the observational period, with 10.4% of the cohort withdrawing from treatment due to intolerance of aquaretic side effects. Most patients maintained a lower tolvaptan dosage (≤45/15 mg) than in clinical trials, with two thirds of individuals who underwent dosage adjustment undergoing net decrease in dosage. Adverse effects significantly influenced and dosage decisions, presenting a potential early barrier for adherence, particularly in female patients. Conclusions The study highlights real-world challenges in the use of tolvaptan for ADPKD, particularly for side effects leading to high discontinuation rates and dosage adjustments. These findings underscore the need for standardized and improved management strategies to enhance tolerability and adherence, offering insights for future research and practice in the treatment of ADPKD with tolvaptan.
Postgraduate medical journal · 2025
Abstract Background Human immunodeficiency virus (HIV), while now manageable as a chronic health condition with highly active antiretroviral therapy (HAART), often precipitates the onset of neurological comorbidities such as HIV-associated neurocognitive disorders (HAND) and a number of neuropathies. ART, though effective, may lead to neurotoxic adverse drug reactions, impacting patient adherence and clinical outcomes. Innovative approaches are warranted to balance ART efficacy with minimized neurological risk. Objective This paper investigates how artificial intelligence (AI) may improve telemedicine for individualized ART management to reduce neurotoxicity and raise patient adherence to medication regimes. Methods A comprehensive literature review was conducted using PubMed/MEDLINE, and Google Scholar, among other electronic search databases, with keywords comprising “Artificial Intelligence,” “Telemedicine,” “HIV,” and “Neurological Comorbidities.” Studies were selected based on relevance to AI applications in personalized HIV care. Inclusion criteria included peer-reviewed articles, systematic reviews, and clinical trials on AI in HIV care. Exclusion criteria omitted non-peer-reviewed articles and studies lacking direct AI relevance. Titles and abstracts were screened before full-text review. Results There is potential for individualized ART management with AI-integrated telemedicine. By anticipating clinical concerns pertaining to ART-associated neurotoxicity, machine learning systems allow for preemptive therapeutic modifications. Wearable technology and AI-powered mHealth apps enable real-time adherence and symptom monitoring, facilitating the prompt adjustments to therapy if necessitated whilst lowering neurotoxic adverse drug reactions. Conclusions AI-enhanced telemedicine promotes customized ART regimens that bolster clinical outcomes and individual quality of life, providing a revolutionary approach to HIV management in populations affected by neurological sequalae. In order to provide fully personalized HIV care, future research should concentrate on improving AI model accuracy across a range of demographics while tackling moral issues pertaining to patient confidentiality and data privacy.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Oncogenesis · 2026 · Journal Article
Lindemann VL, Noureddine N, Morscher RJ
Journal of child and adolescent psychopharmacology · 2026 · Journal Article
Wang C, Lynch S, Noureddine C, Burlant N, et al.
Journal of the American Academy of Child and Adolescent Psychiatry · 2026 · Editorial
Diaz AD, Leong AW, Bilge-Johnson S, Shapiro M, et al.
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus · 2026 · Journal Article
Al-Haddad C, Kobeissi H, Wehbi Z, Slim A, et al.
Journal of pediatric nursing · 2025 · Journal Article
Avedissian T, Noureddine S, Badr LK, Fares S, et al.
EcoHealth · 2025 · Journal Article
Dib I, Noureddine H, Fakih M, Livet A, et al.
Annals of pediatric cardiology · 2025 · Journal Article
Avedissian T, Noureddine S, Bulbul Z, Moons P, et al.
Journal of virology · 2026 · Journal Article
Diego JG-B, Arranz-Herrero J, Laghlali G, Burgess E, et al.
Communications medicine · 2025 · Journal Article
Daou T, El Hadi N, Mansour F, Sarieddine D, et al.
bioRxiv : the preprint server for biology · 2025 · Journal Article
Diego JG, Arranz-Herrero J, Laghlali G, Burgess E, et al.
Nanoscale advances · 2025 · Journal Article
N V, Sekaran S, Suresh Babu R, Sudhakar S, et al.
British journal of clinical pharmacology · 2026 · Journal Article
Naseralallah L, Aboujabal B, Noureddine Z, Aboujabal K, et al.
Clinical therapeutics · 2025 · Journal Article
Koraysh S, Naseralallah L, Noureddine Z, Al-Saadi M, et al.
EcoHealth · 2025 · Journal Article
Dib I, Noureddine H, Fakih M, Livet A, et al.
The Journal of cardiovascular nursing · 2025 · Journal Article
Younes K, Massouh A, Deek H, Nasreddine L, et al.
Postgraduate medical journal · 2025 · Journal Article
Mugisha N, Uwishema O, Fatokun BS, Noureddine R, et al.
Annals of pediatric cardiology · 2025 · Journal Article
Avedissian T, Noureddine S, Bulbul Z, Moons P, et al.
Health science reports · 2025 · Journal Article
Mugisha N, Ghanem L, Komi OAI, Noureddine R, et al.
The British journal of ophthalmology · 2026 · Journal Article
Saade J, Kheir WJ, Hassoun M, Al Hassan S, et al.
Cureus · 2025 · Case Reports
Zeineddine F, Rachid A, Noureddine MR, Mohanna A, et al.
BMC medical genomics · 2026 · Journal Article
Aqillouch S, Laazaazia O, Ouladlahsen A, Noureddine R, et al.
International journal of immunogenetics · 2025 · Journal Article
Noureddine R, Haddaji A, Baba H, Ouladlahsen A, et al.
Psychiatric services (Washington, D.C.) · 2026 · Journal Article
Koire A, Nickel GC, Noureddine C, Liu CH
Pacing and clinical electrophysiology : PACE · 2026 · Journal Article
Darweesh R, Noureddine S, Puzantian H, Refaat M
The Journal of the Association of Physicians of India · 2025 · Journal Article
Rao VK, N T, Rs M
GeroScience · 2025 · Journal Article
Ashiqueali SA, Hayslip N, Chaudhari DS, Schneider A, et al.
Archives of osteoporosis · 2025 · Journal Article
N BV, A MS, A DR, H SG, et al.
Psychiatric services (Washington, D.C.) · 2026 · Journal Article
Koire A, Nickel GC, Noureddine C, Liu CH
Annals of pediatric cardiology · 2025 · Journal Article
Avedissian T, Noureddine S, Bulbul Z, Moons P, et al.
Diabetes · 2026 · Journal Article
Slika A, Noureddine M, Jomaa D, Abboud EE, et al.
Cureus · 2026 · Case Reports
R S, Nanda M S, Adalarasan S, Subramanian Y, et al.
Kidney360 · 2025 · Journal Article
Rao V, Ammar S, Alshorman A, Fravel M, et al.
Australian critical care : official journal of the Confederation of Australian Critical Care Nurses · 2025 · Journal Article
Jannoun N, Noureddine S, Puzantian H, Zeineldine S